[2020 TEIN/KOICA] Summer Workshop for Vietnam ( Session 2)

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the practical implementation of PRRT, including a detailed description of the infusion protocol and the rationale behind using a syringe pump to minimize residual radioactivity. The speaker effectively argues for the efficacy of PRRT based on clinical trial evidence, such as the NETTER-1 trial, and highlights ongoing research that may broaden its indications. The argumentation is logical and grounded in clinical experience, though it relies heavily on expert opinion and does not delve into statistical details or potential biases of the cited trials.

Scientific Rigor, Source Quality, Title Accuracy

The speaker references several key clinical trials (NETTER-1, NETTER-2, COMPETE, VISION) and mentions the European Neuroendocrine Tumor Society (ENETS) guidelines. However, specific citations or URLs are not provided in the video description, limiting the ability to verify sources directly. The title accurately reflects the content, which is a workshop session on theranostics. The presentation is scientifically rigorous in its overview of current evidence, but the lack of explicit references and the informal setting reduce its overall scientific rigor.

The title accurately reflects the content: a workshop session on clinical applications of theranostics, specifically focusing on PRRT and PSMA-targeted therapy.

7/10

The presentation is given by a clinical expert in nuclear medicine, sharing first-hand experience from a clinical trial and reviewing current literature. The content is consistent with established medical knowledge, but lacks detailed citations and peer-reviewed references.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction and overview of the session on clinical application of radiotheranostics.
• 02:00First clinical trial of Lutetium-177-DOTATATE in Korea: patient case and treatment protocol.
• 10:00Discussion on the increasing interest in radiotheranostics from pharmaceutical companies.
• 15:00Neuroendocrine tumors: diagnosis, biomarkers, and imaging techniques.
• 25:00Treatment landscape for NETs: somatostatin analogs, targeted therapy, and PRRT.
• 35:00NETTER-1 trial and FDA approval of Lutathera; ongoing trials NETTER-2 and COMPETE.
• 45:00Prostate cancer: PSMA-targeted therapy with Lu-177-PSMA-617 and the VISION trial.
• 55:00Challenges in response evaluation and personalized dosimetry.
• 1:00:00Future diagnostic approaches: fibroblast activation protein (FAP) as a pan-tumor target.
• 1:05:00Conclusion: timeline from first-in-human studies to clinical application in Korea.

• NETTER-1 trial — Phase 3 trial demonstrating efficacy of Lu-177-DOTATATE in neuroendocrine tumors.
• NETTER-2 trial — Ongoing trial evaluating Lu-177-DOTATATE as first-line therapy in grade 2/3 NETs.
• COMPETE trial — Ongoing trial comparing Lu-177-DOTATATE with everolimus in NETs.
• VISION trial — Phase 3 trial of Lu-177-PSMA-617 in metastatic castration-resistant prostate cancer.
• ENETS guidelines — European Neuroendocrine Tumor Society consensus guidelines for NET management.

• NETTER-1 trial publication — Primary publication of the NETTER-1 trial, supporting the efficacy of Lu-177-DOTATATE.
• VISION trial publication — Primary publication of the VISION trial, supporting Lu-177-PSMA-617 in mCRPC.